Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs Summit Therapeutics Inc (SMMT) Price & Performance

Blackrock IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs Summit Therapeutics Inc — how do they compare? Blackrock Inc trades at $1,154.12 (market cap $177.92B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Blackrock Inc is far larger — about 14.8× Summit Therapeutics Inc's market cap, and Blackrock Inc pays a 2% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

BLKSMMT
Market Cap
$177.92B$12.06B
Volume
641,547
Sector
FinancialsHealth
52-Week High
$1.20K$26.98
52-Week Low
$922.90$12.55
Enterprise Value
$179.02B$11.39B
Dividend Yield
2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

BLK trades at $1,159.09, up 2.45% today, with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with Nvidia and other Wall Street firms, signaling strategic positioning in emerging technology investments.

Outlook remains positive with analyst consensus at Buy (78.79%) and a $1,350 price target, though overbought RSI levels and legal scrutiny over mutual fund practices present near-term risks. The company's expansion into tokenized money market products and sustained dividend payments support long-term growth, but investors should monitor margin pressures and regulatory developments.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT